Targeted agents, such as anti-VEGF medications like bevacizumab, are used alongside chemotherapy to improve patient outcomes by blocking the blood supply to tumors and slowing their growth, particularly in local tumor management and in delaying disease progression (45–47). Here, VEGFA is linked to neoplasm.